Associated Papers
Differential metabolism of citalopram by 21 CYP3A4 variants: An in vitro experiment.
Wang P et al.
Journal of Psychopharmacology (oxford, England), 2025
Decoding Allosteric Effects of Missense Variations in Drug Metabolism: Afrocentric CYP3A4 Alleles Explored.
Mwaniki RM et al.
Journal of Molecular Biology, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Investigation of genetic polymorphisms in pig cytochromes P450 1A2, 2A19, 2C33, 2D25, and 3A22 to elucidate inter-individual variability of hepatic drug oxidations.
Uno Y et al.
Biochemical Pharmacology, 2025
In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.
Abdelazim AA et al.
Scientific Reports, 2025
Effects of CYP3A4 Variants on Methadone Metabolism In Vitro.
Wang CC et al.
Biomedical Chromatography : Bmc, 2025
Effect of recombinant CYP3A4 variants and interaction on imatinib metabolism in vitro.
Chen J et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population.
Hu X et al.
Peerj, 2024
The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone.
Li Q et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2023
Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine.
Zhang X et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro.
Xie SL et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q et al.
Fundamental & Clinical Pharmacology, 2022
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q et al.
Frontiers in Pharmacology, 2022
Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions.
Kong Q et al.
Frontiers in Pharmacology, 2022
Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.
Han M et al.
Chemico-biological Interactions, 2021
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation.
Kumondai M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Crystal Structures of Drug-Metabolizing CYPs.
Estrada DF et al.
Methods in Molecular Biology (clifton, N.j.), 2021
Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism.
Chen B et al.
Chemical Research in Toxicology, 2020
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF et al.
Drug Design, Development and Therapy, 2020
Association between CYP3A4 gene rs4646437 polymorphism and the risk of hypertension in Chinese population: a case-control study.
Wang J et al.
Bioscience Reports, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
Yang CC et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2019
Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro.
Zhou XY et al.
Frontiers in Pharmacology, 2019
Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Xu RA et al.
Basic & Clinical Pharmacology & Toxicology, 2018
Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro.
Fang P et al.
Drug Design, Development and Therapy, 2017
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N et al.
Meta Gene, 2016
CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin.
Kolovou G et al.
Genetics and Molecular Biology, 2015
Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.
Novillo A et al.
The International Journal of Biological Markers, 2015
Functional gene variants of CYP3A4.
Werk AN et al.
Clinical Pharmacology and Therapeutics, 2014
Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.
Kohlrausch FB et al.
Molecular Biology Reports, 2014
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.
Preissner SC et al.
Plos One, 2013
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
Wang D et al.
Journal of Personalized Medicine, 2012
Clinical response to statins: mechanism(s) of variable activity and adverse effects.
Sirtori CR et al.
Annals of Medicine, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O et al.
Human Genomics, 2011
Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential.
Liu D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
Smith NF et al.
The Annals of Pharmacotherapy, 2010
Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A et al.
Dna and Cell Biology, 2010
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.
Uttayamakul S et al.
Aids Research and Therapy, 2010
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density.
Kang YS et al.
Clinical Pharmacology and Therapeutics, 2009
Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
Miyazaki M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2008
Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants.
Peters EJ et al.
Pharmacogenomics, 2008
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Sai K et al.
Cancer Chemotherapy and Pharmacology, 2008